Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
TEMPO Trials: Tavapadon Marches on in Parkinson’s Disease
PHILADELPHIA — Tavapadon, an experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson’s disease (PD), was shown to significantly reduce disease burden in two phase 3 trials TEMPO trials. In the TEMPO-3 trial, topline findings reported earlier this…
English